SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care

First and only melanoma gene expression profiling test that is both: Designated as an FDA Breakthrough Device and included in the NCCN guidelines for T1b and T2a cutaneous melanoma patients. FDA Breakthrough Designation acknowledges Merlin CP-GEP's ability to…

Read the full release →

News provided by PR Newswire.